Drug Profile

SCO 267

Alternative Names: SCO-267

Latest Information Update: 04 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer SCOHIA PHARMA
Class Amides; Antihyperglycaemics; Benzene derivatives; Cycloparaffins; Ethers; Obesity therapies; Piperidines; Propionic acids; Pyridines
Mechanism of Action FFAR1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

04 Aug 2023 Chemical structure information added
01 Aug 2023 SCO 267 is still in phase I trials for obesity in Japan (PO) (Scohia Pharma pipeline, August 2023)
01 Aug 2023 SCO 267 is still in phase I trials for non-alcoholic steatohepatitis in Japan (PO) (Scohia Pharma pipeline, August 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com